MarketCapExport financials
Vir Biotechnology (VIR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Vir Biotechnology Balance Sheet 2025-2011 | VIR
Brief balance sheet overview of Vir Biotechnology
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets fell from $2 billion to $1 billion. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities followed the scale of the balance sheet: -54.5% versus -48.7% for assets. Leverage did not change materially.
The equity ratio reached 76.3% from 73.3%. A high capital share reduces dependence on liabilities.
The period ended with net cash: net debt stood at -$134.3 million. This supports financial flexibility.
The cash reserve occupies 23.2% of the balance sheet, previously 17.8%. It is one marker of short-term resilience.
The accumulated result is -$1.2 billion and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
Taken together, the figures indicate acceptable resilience for Vir Biotechnology. The next assessment depends on debt and equity trends.
Annual Balance Sheet Vir Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-134 M | -125 M | -117 M | -721 M | -210 M | -366 M | -109 M | -47.6 M | -188 M | - | - | - | - | - | - |
Long Term Debt |
89.1 M | 90.1 M | 112 M | 124 M | 134 M | 66.6 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
8.8 M | 7.75 M | 12.9 M | 4.14 M | 3.93 M | 3.62 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 28.9 M | 331 M | 308 M | - | - | - | - | - | - |
Total Current Liabilities |
92.8 M | 120 M | 175 M | 511 M | 341 M | 99.1 M | 59.2 M | - | - | - | - | - | - | - | - |
Total Liabilities |
238 M | 248 M | 329 M | 724 M | 522 M | 202 M | 88.1 M | 371 M | 320 M | - | - | - | - | - | - |
Deferred Revenue |
- | 12.6 M | 64.9 M | 15.5 M | 98.2 M | 6.45 M | 6.18 M | 8.76 M | - | - | - | - | - | - | - |
Retained Earnings |
-1.2 B | -760 M | -238 M | 377 M | -139 M | - | -369 M | -194 M | -78 M | - | - | - | - | - | - |
Total Assets |
1 B | 1.4 B | 1.92 B | 2.8 B | 1.95 B | 919 M | 512 M | 192 M | 252 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
232 M | 223 M | 242 M | 849 M | 348 M | 437 M | 109 M | 47.6 M | 189 M | - | - | - | - | - | - |
Book Value |
765 M | 1.15 B | 1.59 B | 2.08 B | 1.43 B | 717 M | 424 M | -179 M | -68.9 M | - | - | - | - | - | - |
Total Shareholders Equity |
765 M | 1.15 B | 1.59 B | 2.08 B | 1.43 B | 717 M | 424 M | -179 M | -68.9 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Vir Biotechnology
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
84.1 M | 86.6 M | 91.2 M | 93.4 M | 88.2 M | 90.1 M | 93.4 M | 95 M | 109 M | 112 M | 114 M | 118 M | 121 M | 124 M | 127 M | 130 M | 133 M | 134 M | 68.6 M | 68.9 M | 66.6 M | 700 K | 700 K | 800 K | 800 K | 900 K | 900 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
232 M | 213 M | 223 M | 245 M | 264 M | 248 M | 258 M | 236 M | 247 M | 329 M | 370 M | 434 M | 695 M | 724 M | 546 M | 667 M | 886 M | 522 M | 334 M | 320 M | 485 M | 202 M | 202 M | 202 M | 202 M | 88.1 M | 88.1 M | 88.1 M | 88.1 M | 61.6 M | 61.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 10.1 M | 11.9 M | 12.6 M | 15.2 M | 16.7 M | 14.7 M | 64.9 M | 15.3 M | 15.7 M | 17.2 M | 15.5 M | 22.9 M | 113 M | 114 M | 98.2 M | 96.2 M | 44.7 M | 263 M | 6.45 M | 6.45 M | 6.45 M | 6.45 M | 6.18 M | 6.18 M | 6.18 M | 6.18 M | 8.76 M | 8.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.24 B | -1.32 B | -1.15 B | -992 M | -881 M | -760 M | -655 M | -441 M | -303 M | -238 M | -122 M | 41.6 M | 236 M | 377 M | 479 M | 304 M | 380 M | -139 M | -664 M | 774 M | -836 M | -667 M | -667 M | 667 M | -667 M | -369 M | -369 M | -369 M | -369 M | -194 M | -194 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.21 B | 1.03 B | 1.02 B | 1.19 B | 1.31 B | 1.4 B | 1.5 B | 1.67 B | 1.79 B | 1.92 B | 2.04 B | 2.24 B | 2.67 B | 2.8 B | 2.7 B | 2.62 B | 2.89 B | 1.95 B | 1.21 B | 1.06 B | 1.14 B | 919 M | 919 M | 919 M | 919 M | 512 M | 512 M | 512 M | 512 M | 192 M | 192 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
279 M | 274 M | 170 M | 211 M | 274 M | 223 M | 168 M | 297 M | 161 M | 242 M | 452 M | 667 M | 825 M | 849 M | 964 M | 1.51 B | 812 M | 348 M | 715 M | 742 M | 521 M | 451 M | 437 M | 437 M | 437 M | 109 M | 109 M | 109 M | 109 M | 47.6 M | 47.6 M | - | - | 188 M | - | - | - | 14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
982 M | 813 M | 796 M | 947 M | 1.04 B | 1.15 B | 1.24 B | 1.43 B | 1.55 B | 1.59 B | 1.68 B | 1.81 B | 1.97 B | 2.08 B | 2.15 B | 1.95 B | 2 B | 1.43 B | 876 M | 737 M | 651 M | 717 M | 717 M | 717 M | 717 M | 424 M | 424 M | 424 M | 424 M | 130 M | 130 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
982 M | 813 M | 796 M | 947 M | 1.04 B | 1.15 B | 1.24 B | 1.43 B | 1.55 B | 1.59 B | 1.68 B | 1.81 B | 1.97 B | 2.08 B | 2.15 B | 1.95 B | 2 B | 1.43 B | 876 M | 737 M | 651 M | 717 M | 717 M | 717 M | 717 M | 424 M | 424 M | 424 M | 424 M | -179 M | -179 M | -122 M | - | -68.9 M | - | - | - | -7.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Vir Biotechnology, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
